Profile of:

Daniël Wendling

Full name: Daniël Wendling

Current country: France

Membership level: Full

Type of membership: Member

Number of publications: 32

Uveitis occurrence in early inflammatory back pain. Five years data from the prospective French nationwide DESIR cohort (2020)

Can SARS-CoV-2 trigger reactive arthritis? (2020)

ASAS Health Index: The “All in One” for Spondyloarthritis Evaluation? (2020)

Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis. (2020)

From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition. (2020)

Toward a tailored therapeutic prescription for patients with axial spondyloarthritis. (2020)

Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases. (2020)

Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. (2020)

Share Reactive Arthritis: Treatment Challenges and Future Perspectives. (2020)

Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches. (2020)

Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. (2020)

Are the recommendations for the use of anti-TNF drugs during axial spondyloarthritis relevant for non-radiographic forms? (2020)

Ultrasonographic Involvement of the anterior chest wall in Spondyloarthritis: Factors associated with 5-years structural progression. A prospective study in 58 patients. (2020)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. (2020)

Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. (2020)

Cardiovascular risk in psoriatic arthritis, a narrative review. (2020)

Effects of anti-IL-23 and anti-IL-17: The hidden side of spondyloarthritis polymorphism? (2020)

Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence? (2020)

Effect of Gut Involvement in Patients with High Probability of Early Spondyloarthritis: Data from the DESIR Cohort. (2020)

New targeted therapies in spondyloarthritis: what are the limits? (2019)

Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort. (2019)

Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. (2019)

Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. (2019)

Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. (2019)

Aerobic exercise for axial spondyloarthritis – its effects on disease activity and function as compared to standard physiotherapy: A systematic review and meta-analysis. (2019)

Vascular involvement in axial spondyloarthropathies. (2019)

Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. (2018)

2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. (2018)

Disease activity in ankylosing spondylitis: the global therapeutic target. (2018)

Spondyloarthritis: An expanding cast of cellular actors. (2018)

Spondyloarthritis: Harlequin or Chameleon? (2017)

Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009. (2017)